| Lipid nanoparticles for cancer therapy: state of the art and future prospects B Lasa-Saracibar, A Estella-Hermoso de Mendoza, M Guada, ... Expert opinion on drug delivery 9 (10), 1245-1261, 2012 | 88 | 2012 |
| Efficacy of edelfosine lipid nanoparticles in breast cancer cells MÁ Aznar, B Lasa-Saracíbar, AEH de Mendoza, MJ Blanco-Prieto International journal of pharmaceutics 454 (2), 720-726, 2013 | 42 | 2013 |
| Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies M Guada, B Lasa-Saracíbar, H Lana, M del Carmen Dios-Viéitez, ... International Journal of Pharmaceutics 500 (1-2), 154-161, 2016 | 35 | 2016 |
| Lipid nanoparticles protect from edelfosine toxicity in vivo B Lasa-Saracíbar, MÁ Aznar, H Lana, I Aizpún, AG Gil, MJ Blanco-Prieto International journal of pharmaceutics 474 (1-2), 1-5, 2014 | 34 | 2014 |
| Edelfosine lipid nanoparticles overcome multidrug resistance in K-562 leukemia cells by a caspase-independent mechanism MÁ Aznar, B Lasa-Saracíbar, MJ Blanco-Prieto Molecular Pharmaceutics 11 (8), 2650-2658, 2014 | 29 | 2014 |
| Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines B Lasa-Saracíbar, AEH de Mendoza, F Mollinedo, MD Odero, ... Cancer letters 334 (2), 302-310, 2013 | 25 | 2013 |
| In vitro intestinal co-culture cell model to evaluate intestinal absorption of edelfosine lipid nanoparticles B Lasa-Saracíbar, M Guada, V Sebastián, M J Blanco-Prieto Current topics in medicinal chemistry 14 (9), 1124-1132, 2014 | 22 | 2014 |
| Lipid nanoparticles in biomedicine AEH de Mendoza, B Lasa-Saracibar, MA Campanero, M Blanco-Prieto Encycl Nanosci Nanotechnol 15, 455-78, 2010 | 8 | 2010 |
| In vivo biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99 m: Comparison of administration routes in mice B Lasa-Saracíbar, SH El Moukhtari, T Tsotakos, S Xanthopoulos, ... European Journal of Pharmaceutics and Biopharmaceutics 175, 1-6, 2022 | 5 | 2022 |
| Alquil-lysophospholipids and cancer: development of lipid nanoparticles for oral administration and preclinical studies B Lasa-Saracibar | | 2016 |
| In vitro intestinal co-culture cell model to evaluate intestinal absorption of edelfosine lipid nanoparticles MJ Blanco-Prieto, V Sebastian, M Guada, B Lasa-Saracibar Bentham Science Publishers, 2014 | | 2014 |
| Lipid nanoparticles for cancer therapy: state of the art and future prospects MJ Blanco-Prieto, MC Dios-Vieitez, M Guada, ... Informa Healthcare, 2012 | | 2012 |
| Lipid Nanoparticles in Biomedicine A Estella-Hermoso de Mendoza, B Lasa-Saracibar, MA Campanero, ... Encyclopedia of Nanoscience and Nanotechnology 15 (478), 455-478, 2011 | | 2011 |
| Edelfosine Lipid Nanoparticles overcome MDR in K-562 leukemia cells by caspase-independent mechanism B Lasa-Saracíbar, MÁ Aznar, MJ Blanco-Prieto Alquil-lysophospholipids and cancer: development of lipid nanoparticles for …, 0 | | |
| In vivo biodistribution of edelfosine radio-labeled lipid nanoparticles and efficacy in xenogeneic mouse model of human acute lymphoblastic leukemia B Lasa-Saracíbar, S Xanthopoulos, T Theodore, A Vilas-Zornoza, ... Alquil-lysophospholipids and cancer: development of lipid nanoparticles for …, 0 | | |
| In vivo toxicity evaluation of lipid nanoparticles loaded with edelfosine B Lasa-Saracíbar, MÁ Aznar, H Lana, I Aizpún, A Gloria, MJ Gil Alquil-lysophospholipids and cancer: development of lipid nanoparticles for …, 0 | | |
